Freedom Broker keeps MNTN at Buy but trims target to $9
Freedom Broker reaffirmed its Buy rating on MNTN and cut its price target to $9 from $16.50, a 45.5% reduction, as reported by TradingView on November 7.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Freedom Broker kept its Buy recommendation on MNTN but lowered its price target to $9 from $16.50, a reduction of 45.5%. With the stock closing at $5.33 on November 6, the new target implies a 68.9% upside, according to TradingView, which relays Benzinga data.
Other recent views on the stock are more cautious. Citigroup cut its rating to Neutral with a $7 target on November 5, and Citizens moved the shares to Market Perform the same day. Susquehanna kept a Positive stance with a $12 target. Across the last four notes, targets span from $7 to $16.50.
why it matters
The spread of opinions is wide for investors following the name: the lowest target is $7, while the highest is the $16.50 that Freedom Broker set when it initiated coverage. The latest cut narrows that gap, but analysts still do not agree.
tags
instruments
sources
- Freedom Broker maintains MNTN at Buy, lowers price target to $9 from $16.50 — TradingView, 7 November 2026 at 00:00 UTC
- Freedom Broker maintains Niagen Bioscience at Buy, lowers price target to $6 from $8.50 — TradingView, 6 November 2026 at 23:56 UTC
- Freedom Broker maintains Intrepid Potash at Buy, lowers price target to $40 from $41 — TradingView, 7 November 2026 at 00:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗